TSHA Taysha Gene Therapies
- 2.2700
- -0.1400-5.81%
- 2.4203
- +0.1503+6.62%
Taysha Gene Therapies News
Taysha Gene Therapies Analyst Ratings
Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
Taysha Gene Therapies Analyst Ratings
Needham: Reiterates Taysha Gene Therapies (TSHA.US) rating and adjusted from buy to buy rating, target price is $7.00.
Taysha Gene Therapies (TSHA.US) was covered for the first time by Piper Sandler, with an increase in holdings rating, with a target price of $9.00.
Taysha Gene Therapies Analyst Ratings
Piper Sandler Initiates Coverage On Taysha Gene Therapies With Overweight Rating, Announces Price Target of $9
Taysha Gene Therapies (TSHA) Gets a Buy From Truist Financial
Taysha Gene Therapies Analyst Ratings
Canaccord Genuity Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Positive Clinical Trials Bolster Buy Rating for Taysha Gene Therapies
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
Taysha Gene Therapies Analyst Ratings
Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Health
Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Taysha Gene Therapies Analyst Ratings
Buy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial Stability
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Rett Syndrome Program Developments
Analysis
Price Target
No Data
